title: A single-dose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic patients.
abstract: Treatment with the somatostatin receptor (sst) subtype 2 predominant analogs octreotide and lanreotide induces clinical and biochemical cure in approximately 65% of acromegalic patients. GH-secreting pituitary adenomas, which are not controlled, also express sst(5). We compared the acute effects of octreotide and SOM230, a new somatostatin analog with high affinity for sst(1,2,3,5) on hormone release in acromegalic patients. In a single-dose, proof-of-concept study, 100 microg octreotide and 100 and 250 microg SOM230 were given s.c. to 12 patients with active acromegaly. Doses of 100 and 250 microg SOM230 dose-dependently suppressed GH levels from 2-8 h after administration (-38 +/- 7.7 vs. -61 +/- 6.7%, respectively; P < 0.01). A comparable suppression of GH levels by octreotide and 250 microg SOM230 was observed in eight patients (-65 +/- 7 vs. -72 +/- 7%, respectively). In three patients, the acute GH-lowering effect of 250 microg SOM230 was significantly superior to that of octreotide (-70 +/- 2 vs. -17 +/- 15%, respectively; P < 0.01). In one patient, the GH-lowering effect of octreotide was better than that of SOM230. Tolerability for SOM230 was good. Glucose levels were initially slightly elevated after octreotide and SOM230, compared with control day, whereas insulin levels were only significantly suppressed by octreotide. We conclude that SOM230 is an effective GH-lowering drug in acromegalic patients with the potential to increase the number of patients controlled during long-term medical treatment.
authors.affiliation: Department of Internal Medicine, Section of Endocrinology, Erasmus Medical Center, 3015 GD Rotterdam, The Netherlands. j.vanderhoek@erasmusmc.nl
authors.forename: Joost
authors.initials: J
authors.lastname: van der Hoek
authors.forename: Wouter W
authors.initials: WW
authors.lastname: de Herder
authors.forename: Richard A
authors.initials: RA
authors.lastname: Feelders
authors.forename: Aart-Jan
authors.initials: AJ
authors.lastname: van der Lely
authors.forename: Piet
authors.initials: P
authors.lastname: Uitterlinden
authors.forename: Viktor
authors.initials: V
authors.lastname: Boerlin
authors.forename: Christian
authors.initials: C
authors.lastname: Bruns
authors.forename: Kwai W
authors.initials: KW
authors.lastname: Poon
authors.forename: Ian
authors.initials: I
authors.lastname: Lewis
authors.forename: Gisbert
authors.initials: G
authors.lastname: Weckbecker
authors.forename: Tillmann
authors.initials: T
authors.lastname: Krahnke
authors.forename: Leo J
authors.initials: LJ
authors.lastname: Hofland
authors.forename: Steven W
authors.initials: SW
authors.lastname: Lamberts
mesh_terms: D000172:Acromegaly / Q000188:drug therapy* / Q000378:metabolism*; D000328:Adult; D000368:Aged; D018592:Cross-Over Studies; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D019382:Human Growth Hormone / Q000378:metabolism*; D006801:Humans; D008297:Male; D008875:Middle Aged; D015282:Octreotide / Q000008:administration & dosage* / Q000009:adverse effects; D013004:Somatostatin / Q000008:administration & dosage* / Q000009:adverse effects / Q000031:analogs & derivatives*; D016896:Treatment Outcome; D014407:Tumor Cells, Cultured
chemical_list: D019382:Human Growth Hormone; D013004:Somatostatin; C517782:pasireotide; D015282:Octreotide